185 related articles for article (PubMed ID: 30846465)
21. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
22. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Krymskaya VP; Courtwright AM; Fleck V; Dorgan D; Kotloff R; McCormack FX; Kreider M
Respir Med; 2020 Mar; 163():105898. PubMed ID: 32125970
[TBL] [Abstract][Full Text] [Related]
23. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
24. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
Yoon HY; Hwang JJ; Kim DS; Song JW
Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
[TBL] [Abstract][Full Text] [Related]
28. Lymphangioleiomyomatosis (LAM) presenting as recurrent pneumothorax in an infant with tuberous sclerosis: treated successfully with sirolimus.
Takia L; Jat KR; Mandal A; Kabra SK
BMJ Case Rep; 2018 Nov; 2018():. PubMed ID: 30413450
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
[TBL] [Abstract][Full Text] [Related]
30. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.
Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
[TBL] [Abstract][Full Text] [Related]
31. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
33. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
[TBL] [Abstract][Full Text] [Related]
34. Lymphangioleiomyomatosis (LAM).
Ataya A; Brantly M; Riley L
Am J Respir Crit Care Med; 2018 Aug; 198(4):P7-P8. PubMed ID: 30109949
[No Abstract] [Full Text] [Related]
35. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
36. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
37. Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.
Gopalakrishnan V; Yao J; Steagall WK; Avila NA; Taveira-DaSilva AM; Stylianou M; Chen MY; Moss J
Chest; 2019 May; 155(5):962-971. PubMed ID: 30660784
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
Steagall WK; Stylianou M; Pacheco-Rodriguez G; Moss J
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843885
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
40. The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis.
Gupta N; Lee HS; Ryu JH; Taveira-DaSilva AM; Beck GJ; Lee JC; McCarthy K; Finlay GA; Brown KK; Ruoss SJ; Avila NA; Moss J; McCormack FX;
Chest; 2019 Feb; 155(2):288-296. PubMed ID: 29940164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]